166 related articles for article (PubMed ID: 33576409)
1. Sodium-glucose co-transporter 2 inhibitors in heart failure.
Rosano GMC; Vitale C; Savarese G
Eur Heart J Cardiovasc Pharmacother; 2021 May; 7(3):e9-e10. PubMed ID: 33576409
[No Abstract] [Full Text] [Related]
2. The far-reaching beneficial effects of sodium-glucose co-transporter 2 inhibitors in heart failure.
Crea F
Eur Heart J; 2022 Aug; 43(31):2907-2910. PubMed ID: 35963617
[No Abstract] [Full Text] [Related]
3. Treatment of heart failure: the dawn of the era of sodium-glucose co-transporter-2 inhibitors.
Crea F
Eur Heart J; 2020 Sep; 41(36):3379-3383. PubMed ID: 33216881
[No Abstract] [Full Text] [Related]
4. Sodium-glucose co-transporter 2 inhibitors for heart failure: clinical trial efficacy and clinical practice effectiveness.
Khan MS; Fonarow GC; Greene SJ
Eur J Heart Fail; 2021 Jun; 23(6):1023-1025. PubMed ID: 33779013
[No Abstract] [Full Text] [Related]
5. Sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism.
Anker SD; Khan MS; Shahid I; Filippatos G; Coats AJS; Butler J
Eur J Heart Fail; 2021 Aug; 23(8):1250-1255. PubMed ID: 34173305
[No Abstract] [Full Text] [Related]
6. Sodium-glucose co-transporter 2 inhibitors-the first successful treatment for heart failure with preserved ejection fraction?
Petrie MC; Lee MMY; Docherty KF
Eur J Heart Fail; 2021 Aug; 23(8):1256-1259. PubMed ID: 33502794
[No Abstract] [Full Text] [Related]
7. Sodium-glucose co-transporter 2 inhibitors and heart failure-the present and the future.
Nana M; Morgan H; Bondugulapati LNR
Heart Fail Rev; 2021 Jul; 26(4):953-960. PubMed ID: 32020487
[TBL] [Abstract][Full Text] [Related]
8. Meta-Analysis Evaluating the Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Acute or Recently Decompensated Heart Failure.
Patoulias D; Doumas M; Kassimis G; Fragakis N; Papadopoulos C
Am J Cardiol; 2022 Jun; 172():171-172. PubMed ID: 35396145
[No Abstract] [Full Text] [Related]
9. Totality of evidence in trials of sodium-glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice.
Butler J; Zannad F; Filippatos G; Anker SD; Packer M
Eur Heart J; 2020 Sep; 41(36):3398-3401. PubMed ID: 32935133
[No Abstract] [Full Text] [Related]
10. Pharmacology Focus: Clinical Evidence for the Use of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction.
Berendse J; Newenhouse L
S D Med; 2022 Jul; 75(7):328-329. PubMed ID: 36542574
[No Abstract] [Full Text] [Related]
11. Sodium-Glucose Co-Transporter-2 Inhibitor Therapy During Anthracycline Treatment: Is There a Role for Cardioprotection?
Khouri MG; Greene SJ
JACC Heart Fail; 2022 Aug; 10(8):568-570. PubMed ID: 35902160
[No Abstract] [Full Text] [Related]
12. The Time Is Now for Sodium Glucose Co-Transporter 2 Inhibitors for Heart Failure: A Call to Overcome Clinical Inertia.
Khan MS; Butler J; Greene SJ
Circ Heart Fail; 2020 Dec; 13(12):e008030. PubMed ID: 33161728
[No Abstract] [Full Text] [Related]
13. Sodium-Glucose Co-Transporter-2 Inhibitors Decrease the Odds for Atrial Fibrillation in Subjects with Heart Failure.
Patoulias D; Papadopoulos C; Doumas M
J Stroke Cerebrovasc Dis; 2022 Mar; 31(3):106257. PubMed ID: 34953683
[No Abstract] [Full Text] [Related]
14. Sodium glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: a systematic review and meta-analysis.
Tsampasian V; Elghazaly H; Chattopadhyay R; Ali O; Corballis N; Chousou PA; Clark A; Garg P; Vassiliou VS
Eur J Prev Cardiol; 2022 May; 29(6):e227-e229. PubMed ID: 34850881
[No Abstract] [Full Text] [Related]
15. Shift of conventional paradigm of heart failure treatment: from angiotensin receptor neprilysin inhibitor to sodium-glucose co-transporter 2 inhibitors?
Berezin AE; Berezin AA
Future Cardiol; 2021 May; 17(3):497-506. PubMed ID: 33615880
[TBL] [Abstract][Full Text] [Related]
16. Epicardial adipose tissue: does it mediate the cardio-protective effects of sodium-glucose co-transporter 2 inhibitors in patients with heart failure? Letter regarding the article 'Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure'.
Doumas M; Patoulias D; Papadopoulos C
Eur J Heart Fail; 2022 Feb; 24(2):400-401. PubMed ID: 34989088
[No Abstract] [Full Text] [Related]
17. Sodium-glucose co-transporter 2 inhibitors and mineralocorticoid receptor antagonists synergism in heart failure: it takes two to tango.
Bauersachs J; Soltani S
Eur Heart J; 2023 Oct; 44(37):3697-3699. PubMed ID: 37611060
[No Abstract] [Full Text] [Related]
18. Reply to 'Epicardial adipose tissue: does it mediate the cardio-protective effects of sodium-glucose co-transporter 2 inhibitors in subjects with heart failure?' Letter regarding the article 'Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure'.
De Biase N; Del Punta L; Pugliese NR
Eur J Heart Fail; 2022 Feb; 24(2):401. PubMed ID: 34985799
[No Abstract] [Full Text] [Related]
19. Sodium-glucose co-transporter-2 inhibitors and protection from cardiovascular death: Is it all about heart failure?
Caruso I; Cignarelli A; Laviola L; Giorgino F
Diabetes Obes Metab; 2021 Sep; 23(9):2194-2196. PubMed ID: 34033214
[No Abstract] [Full Text] [Related]
20. Sodium-glucose co-transporter-2 inhibitors eligibility in patients with heart failure with reduced ejection fraction.
Monzo L; Ferrari I; Cicogna F; Tota C; Calò L
Int J Cardiol; 2021 Oct; 341():56-59. PubMed ID: 34454968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
